Chen et al.16 demonstrated that brevilin A is a potential inhibitor of Janus kinase (JAK) activity and STAT signaling in cancer cells, suggesting that brevilin A may be a therapeutic agent for the cancer patients with hyperactivated JAKs and STATs. This evidence concerns the gene SOAT1 and cancer.